Equels Thomas K

Executive buyer

Director, CEO & President · AIM ImmunoTech Inc.

Every open-market stock purchase Equels Thomas K has reported to the SEC on Form 4 that met our signal bar, parsed straight from the filings. This page tracks where how the prices paid compare to where the stock trades now.

Total bought

$26.8K

Open-market buys

Companies

Last buy

Nov 6, 2026

Where the buys stand today

AIM
AIM ImmunoTech Inc.
7 purchases totalling $26.8K at an average of $0.18 per share. See all insider buying in AIM →
Avg price paid
$0.18
Latest price
—
Market cap
Unknown

All reported buys

Date	Ticker	Shares	Price	Value	Filing
Nov 6, 2026	AIM	20,299	$0.16	$3.2K	SEC ↗
Oct 23, 2026	AIM	31,675	$0.16	$5.1K	SEC ↗
Oct 22, 2026	AIM	31,250	$0.16	$5.1K	SEC ↗
Sep 17, 2026	AIM	24,000	$0.21	$5.0K	SEC ↗
Sep 16, 2026	AIM	11,000	$0.21	$2.3K	SEC ↗
Sep 15, 2026	AIM	22,000	$0.22	$4.9K	SEC ↗
Sep 14, 2026	AIM	5,900	$0.22	$1.3K	SEC ↗

Follow new qualifying clusters involving Equels Thomas K or other insiders

Explore qualifying clusters from public SEC filings. Pro adds email and Telegram notifications after detection.

Start a trial See pricing

About this data

Figures are parsed from Equels Thomas K's Form 4 filings on SEC EDGAR (CIK 1450324) and cover open-market purchases (transaction code P) — grants, option exercises, and sales are excluded, which is why totals here can differ from raw filing counts. Every row links to its source document.

This page is informational and reflects public filing data. It is not investment advice.